Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative drugs function by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to food. By activating GLP-1 receptors in the pancreas, these substances increase insulin secretion and inhibit glucag

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant recognition. These medications offer promising strategies for controlling blood sugar levels and could improve the lives of individuals living with diabetes. This novel class